

Docket No. 264163US0PCT

MAR 04 2005

JC76

PTO-904

U.S. PATENT & TRADEMARK OFFICE

DT07 Rec'd PCT/PTO 04 MAR 2005 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Takao FUJIMURA, et al.

SERIAL NO: 10/519,678

GAU:

FILED: January 7, 2005

EXAMINER:

FOR: NOVEL METHOD OF SELECTING IMMUNOSUPPRESSANT HAVING LITTLE THROMBOCYTOPENIC EFFECT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Surinder Sachar

Norman F. Oblon
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar
Registration No. 34,423



SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 264163US0PCT	SERIAL NO. 10/519,678		
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Takao FUJIMURA, et al.					
		FILING DATE January 7, 2005		GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AO	00/08048	02/17/00	WO	YES	NO	
	AP						
	AQ						
	AR						
	AS						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AT	David M. VIGUSHIN, et al., "Histone deacetylase inhibitors in cancer treatmeant", ANTI-CANCER DRUGS, vol. 13, no. 1, pages 1-13 2002					
	AU	Ramesh A. Shivedasani, et al., "A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development", THE EMBO JOURNAL, vol. 16, no. 13, pages 3965-3973 1997					
	AV	Paresh Vyas, et al., "Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulartory element upstream of the GATA-1 gene", DEVELOPMENT, vol. 126, pages 2799-2811 05/19/99					
	AW	Shigeko NISHIMURA, et al., "A GATA box in the GATA-1 gene hematopoietic enhancer is a critical element in the network of GATA factors and sites the regulate this gene", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 2, pages 713-723 01/2000					
	AX					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

U.S. PCT Application Serial No.: 10/519,678
Docket No.: 264163US0PCT

STATEMENT OF RELEVANCY

- 1) References AO & AT-AU have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References _____ have been cited in the corresponding_____ Search Report. A copy of these references is being submitted herewith.
- 3) Reference AV-AW are discussed in the specification. A copy of these references is being submitted here with.
- 4) Reference ____ is additional prior art known to Applicant. A copy of the reference will not be submitted herewith.